Stan Erck Sells 47,689 Shares of MaxCyte, Inc. (LON:MXCT) Stock

MaxCyte, Inc. (LON:MXCT) insider Stan Erck sold 47,689 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of GBX 388 ($5.19), for a total value of £185,033.32 ($247,503.10).

MaxCyte Price Performance

Shares of MXCT stock opened at GBX 280 ($3.75) on Friday. The stock has a 50 day moving average of GBX 316.07 and a two-hundred day moving average of GBX 332.60. The company has a current ratio of 14.31, a quick ratio of 14.38 and a debt-to-equity ratio of 8.37. MaxCyte, Inc. has a 12 month low of GBX 180 ($2.41) and a 12 month high of GBX 430 ($5.75). The company has a market capitalization of £294.25 million, a P/E ratio of -1,120.00 and a beta of 1.13.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.